tradingkey.logo

Baxter International Inc

BAX
18.960USD
-0.110-0.58%
收盤 12/19, 16:00美東報價延遲15分鐘
9.74B總市值
虧損本益比TTM

Baxter International Inc

18.960
-0.110-0.58%

關於 Baxter International Inc 公司

Baxter International Inc. is a global medtech company. Its segments include Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of its sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of its connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. It provides a portfolio of diagnostic, critical care, nutrition, hospital and surgical products.

Baxter International Inc簡介

公司代碼BAX
公司名稱Baxter International Inc
上市日期Jun 20, 2097
CEOHider (Andrew P)
員工數量38000
證券類型Ordinary Share
年結日Jun 20
公司地址One Baxter Parkway
城市DEERFIELD
上市交易所NASDAQ OMX NASDAQ Basic NYSE
國家United States of America
郵編60015
電話12249482000
網址https://www.baxter.com/
公司代碼BAX
上市日期Jun 20, 2097
CEOHider (Andrew P)

Baxter International Inc公司高管

名稱
名稱/職務
職務
持股
持股變動
Mr. Andrew P. Hider
Mr. Andrew P. Hider
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
368.05K
--
Dr. Jeanne K. Mason, Ph.D.
Dr. Jeanne K. Mason, Ph.D.
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
141.67K
+7.47%
Mr. David S. Rosenbloom
Mr. David S. Rosenbloom
Executive Vice President, General Counsel
Executive Vice President, General Counsel
101.60K
-14.01%
Dr. Stephen N. (Steve) Oesterle, M.D.
Dr. Stephen N. (Steve) Oesterle, M.D.
Independent Director
Independent Director
35.70K
+25.18%
Ms. Catherine R. (Cathy) Smith
Ms. Catherine R. (Cathy) Smith
Independent Director
Independent Director
30.23K
+31.17%
Ms. Patricia B. (Patty) Morrison
Ms. Patricia B. (Patty) Morrison
Independent Director
Independent Director
22.94K
+45.58%
Mr. Stephen H. (Steve) Rusckowski
Mr. Stephen H. (Steve) Rusckowski
Independent Director
Independent Director
16.45K
+77.49%
Mr. Jeffrey A. (Jay) Craig
Mr. Jeffrey A. (Jay) Craig
Independent Director
Independent Director
10.65K
+206.88%
Ms. Nancy M. Schlichting
Ms. Nancy M. Schlichting
Lead Independent Director
Lead Independent Director
7.97K
+912.71%
Ms. Amy A. Mcbride-Wendell
Ms. Amy A. Mcbride-Wendell
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Andrew P. Hider
Mr. Andrew P. Hider
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
368.05K
--
Dr. Jeanne K. Mason, Ph.D.
Dr. Jeanne K. Mason, Ph.D.
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
141.67K
+7.47%
Mr. David S. Rosenbloom
Mr. David S. Rosenbloom
Executive Vice President, General Counsel
Executive Vice President, General Counsel
101.60K
-14.01%
Dr. Stephen N. (Steve) Oesterle, M.D.
Dr. Stephen N. (Steve) Oesterle, M.D.
Independent Director
Independent Director
35.70K
+25.18%
Ms. Catherine R. (Cathy) Smith
Ms. Catherine R. (Cathy) Smith
Independent Director
Independent Director
30.23K
+31.17%
Ms. Patricia B. (Patty) Morrison
Ms. Patricia B. (Patty) Morrison
Independent Director
Independent Director
22.94K
+45.58%

收入明細

單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
業務USD
名稱
營收
佔比
Infusion Therapies and Technologies
1.02B
36.44%
Care and Connectivity Solutions
474.00M
16.87%
Injectables and Anesthesia
332.00M
11.81%
Advanced Surgery
296.00M
10.53%
Front Line Care
293.00M
10.43%
其他
391.00M
13.91%
地區USD
名稱
營收
佔比
United States
1.54B
54.66%
International
1.27B
45.34%
業務
地區
業務USD
名稱
營收
佔比
Infusion Therapies and Technologies
1.02B
36.44%
Care and Connectivity Solutions
474.00M
16.87%
Injectables and Anesthesia
332.00M
11.81%
Advanced Surgery
296.00M
10.53%
Front Line Care
293.00M
10.43%
其他
391.00M
13.91%

股東統計

更新時間: 11月17日 週一
更新時間: 11月17日 週一
持股股東
股東類型
持股股東
持股股東
佔比
The Vanguard Group, Inc.
12.11%
Dodge & Cox
11.17%
Pzena Investment Management, LLC
11.16%
BlackRock Institutional Trust Company, N.A.
6.09%
BlackRock Financial Management, Inc.
4.80%
其他
54.66%
持股股東
持股股東
佔比
The Vanguard Group, Inc.
12.11%
Dodge & Cox
11.17%
Pzena Investment Management, LLC
11.16%
BlackRock Institutional Trust Company, N.A.
6.09%
BlackRock Financial Management, Inc.
4.80%
其他
54.66%
股東類型
持股股東
佔比
Investment Advisor/Hedge Fund
47.20%
Investment Advisor
44.83%
Hedge Fund
2.90%
Research Firm
2.48%
Pension Fund
1.50%
Insurance Company
1.45%
Bank and Trust
1.22%
Sovereign Wealth Fund
1.14%
Individual Investor
0.46%

機構持股

更新時間: 12月8日 週一
更新時間: 12月8日 週一
報告期間
機構數
持股數
持股佔比
持股變動
2025Q4
1743
527.76M
108.76%
+72.60K
2025Q3
1826
527.84M
110.04%
+1.85M
2025Q2
1880
509.50M
105.73%
+4.72M
2025Q1
1916
504.93M
105.92%
-38.38M
2024Q4
1965
494.73M
105.04%
+14.02M
2024Q3
1980
482.92M
103.29%
+12.67M
2024Q2
2019
470.33M
102.19%
-1.85M
2024Q1
2069
469.00M
102.47%
-52.95M
2023Q4
2111
469.21M
101.33%
+9.34M
2023Q3
2090
463.57M
98.58%
+5.62M
查看更多

股東持股明細

名稱
持股數
佔比
持股變動
變動比例
公告日期
The Vanguard Group, Inc.
61.95M
12.06%
+1.13M
+1.85%
Jun 30, 2025
Dodge & Cox
52.12M
10.15%
+662.70K
+1.29%
Jun 30, 2025
Pzena Investment Management, LLC
55.46M
10.8%
+16.12M
+40.98%
Aug 31, 2025
BlackRock Institutional Trust Company, N.A.
29.85M
5.81%
-423.57K
-1.40%
Jun 30, 2025
BlackRock Financial Management, Inc.
18.73M
3.65%
+742.99K
+4.13%
Jun 30, 2025
State Street Investment Management (US)
21.94M
4.27%
+170.66K
+0.78%
Jun 30, 2025
T. Rowe Price Associates, Inc.
21.21M
4.13%
+1.64M
+8.40%
Jun 30, 2025
Geode Capital Management, L.L.C.
12.88M
2.51%
+326.65K
+2.60%
Jun 30, 2025
BlackRock Investment Management, LLC
7.81M
1.52%
+818.08K
+11.70%
Jun 30, 2025
查看更多

持股ETF

更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
iShares Large Cap Value Active ETF
2.23%
First Trust Indxx Medical Devices ETF
1.69%
Invesco Raymond James SB-1 Equity ETF
1.5%
State Street SPDR S&P Health Care Equipment ETF
1.37%
Invesco S&P 500 Equal Weight Health Care ETF
1.26%
Franklin US Dividend Booster Index ETF
1.26%
iShares U.S. Medical Devices ETF
1.13%
Invesco Zacks Multi-Asset Income ETF
0.8%
Humankind US Stock ETF
0.76%
Pacer CFRA-Stovall Equal Weight Seasonal Rot Idx
0.57%
查看更多
iShares Large Cap Value Active ETF
佔比2.23%
First Trust Indxx Medical Devices ETF
佔比1.69%
Invesco Raymond James SB-1 Equity ETF
佔比1.5%
State Street SPDR S&P Health Care Equipment ETF
佔比1.37%
Invesco S&P 500 Equal Weight Health Care ETF
佔比1.26%
Franklin US Dividend Booster Index ETF
佔比1.26%
iShares U.S. Medical Devices ETF
佔比1.13%
Invesco Zacks Multi-Asset Income ETF
佔比0.8%
Humankind US Stock ETF
佔比0.76%
Pacer CFRA-Stovall Equal Weight Seasonal Rot Idx
佔比0.57%

分紅派息

近5年累計派現 2.75B 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
Nov 11, 2025
BAX.NB Final Cash Dividend of gross USD 0.01 paid on Jan 02, 2026 going ex on Nov 28, 2025 with reinvestment option
Nov 28, 2025
Jan 02, 2026
Nov 28, 2025
Jul 14, 2025
BAX.NB Interim Cash Dividend of gross USD 0.17 paid on Oct 01, 2025 going ex on Aug 29, 2025 with reinvestment option
Aug 29, 2025
Oct 01, 2025
Aug 29, 2025
May 06, 2025
BAX.NB Interim Cash Dividend of gross USD 0.17 paid on Jul 01, 2025 going ex on May 30, 2025 with reinvestment option
May 30, 2025
Jul 01, 2025
May 30, 2025
Feb 11, 2025
BAX.NB Interim Cash Dividend of gross USD 0.17 paid on Apr 01, 2025 going ex on Feb 28, 2025 with reinvestment option
Feb 28, 2025
Apr 01, 2025
Feb 28, 2025
Nov 11, 2024
BAX.NB Final Cash Dividend of gross USD 0.17 paid on Jan 02, 2025 going ex on Nov 29, 2024 with reinvestment option
Nov 29, 2024
Jan 02, 2025
Nov 29, 2024
Jul 16, 2024
BAX.NB Interim Cash Dividend of gross USD 0.29 paid on Oct 01, 2024 going ex on Aug 30, 2024 with reinvestment option
Aug 30, 2024
Oct 01, 2024
Aug 30, 2024
May 07, 2024
BAX.NB Interim Cash Dividend of gross USD 0.29 paid on Jul 01, 2024 going ex on May 31, 2024 with reinvestment option
May 31, 2024
Jul 01, 2024
May 31, 2024
Feb 12, 2024
BAX.NB Interim Cash Dividend of gross USD 0.29 paid on Apr 01, 2024 going ex on Feb 29, 2024 with reinvestment option
Mar 01, 2024
Apr 01, 2024
Feb 29, 2024
Nov 14, 2023
BAX.NB Final Cash Dividend of gross USD 0.29 paid on Jan 02, 2024 going ex on Nov 30, 2023 with reinvestment option
Dec 01, 2023
Jan 02, 2024
Nov 30, 2023
Jul 18, 2023
BAX.NB Interim Cash Dividend of gross USD 0.29 paid on Oct 02, 2023 going ex on Aug 31, 2023 with reinvestment option
Sep 01, 2023
Oct 02, 2023
Aug 31, 2023
查看更多

拆合股

公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據

常見問題

Baxter International Inc的前五大股東是誰?

Baxter International Inc的前五大股東如下:
The Vanguard Group, Inc.
持有股份:61.95M
佔總股份比例:12.06%。
Dodge & Cox
持有股份:52.12M
佔總股份比例:10.15%。
Pzena Investment Management, LLC
持有股份:55.46M
佔總股份比例:10.80%。
BlackRock Institutional Trust Company, N.A.
持有股份:29.85M
佔總股份比例:5.81%。
BlackRock Financial Management, Inc.
持有股份:18.73M
佔總股份比例:3.65%。

Baxter International Inc的前三大股東類型是什麼?

Baxter International Inc 的前三大股東類型分別是:
The Vanguard Group, Inc.
Dodge & Cox
Pzena Investment Management, LLC

有多少機構持有Baxter International Inc(BAX)的股份?

截至2025Q4,共有1743家機構持有Baxter International Inc的股份,合計持有的股份價值約為527.76M,占公司總股份的108.76% 。與2025Q3相比,機構持股有所增加,增幅為-1.28%。

哪個業務部門對Baxter International Inc的收入貢獻最大?

在FY2025Q2,Infusion Therapies and Technologies業務部門對Baxter International Inc的收入貢獻最大,創收1.02B,占總收入的36.44% 。
KeyAI